Document Detail


Molecular epidemiologic features of inflammatory breast cancer: a comparison between Egyptian and US patients.
MedLine Citation:
PMID:  18058225     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Inflammatory breast cancer (IBC) is a lethal form of breast cancer with unknown etiology. A higher frequency of IBC and a more aggressive IBC phenotype was reported in Egypt than in the United States. This difference in disease frequency and presentation might be related to molecular epidemiologic factors.
METHODS: We used tumor blocks and demographic, epidemiologic, and clinical data of 48 IBC patients from Egypt and 12 patients from the United States. We counted tumor emboli in tumors before and after immunohistochemical staining with lymphatic vessel endothelial receptor-1 (LYVE-1), and measured the expression of RhoC GTPase protein in the two groups.
RESULTS: Erythema, edema, and peau d'orange were found in 77% of the Egyptian patients as compared with 29% found in the US patients (P=0.02). The number of tumor emboli was significantly higher in tumors from Egypt (mean+/-SD, 14.1+/-14.0) than in the tumors from the United States (5.0+/-4.0, P=0.01). The number of tumor emboli in LYVE-1 positive vessels was higher in tumors from Egypt (3.5+/-2.8) than tumors from the United States (1.6+/-0.5, P=0.15). We detected a high level of RhoC in 87% of the tumors from Egypt and 14% of the tumors from the United States (P=0.0003).
CONCLUSION: Patients from Egypt have a more aggressive form of IBC than those in the United States. Our analysis of IBC patients shows that distinct molecular phenotypes can be found when these two study populations are compared. Future studies should explore the epidemiologic and environmental exposures and the genetic factors that might lead to the different clinical and molecular features of IBC in patients from these two countries.
Authors:
An-Chi Lo; Celina G Kleer; Mousumi Banerjee; Sherif Omar; Hussein Khaled; Saad Eissa; Ahmed Hablas; Julie A Douglas; Sharon H Alford; Sofia D Merajver; Amr S Soliman
Related Documents :
23738975 - Development of quinic acid-conjugated nanoparticles as a drug carrier to solid tumors.
19410375 - Circulating tumor cells (ctcs): detection methods and their clinical relevance in breas...
23450195 - Tumor size and effectiveness of electrochemotherapy.
23703385 - Antitumor activity of il-32β through the activation of lymphocytes, and the inactivati...
12824515 - Follicular stem cell carcinoma: histologic, immunohistochemical, ultrastructural, and c...
19929675 - Photodynamic therapy for palpebral and conjunctival proliferative vascular tumors: clin...
Publication Detail:
Type:  Comparative Study; Journal Article; Multicenter Study; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't; Research Support, U.S. Gov't, Non-P.H.S.     Date:  2007-12-04
Journal Detail:
Title:  Breast cancer research and treatment     Volume:  112     ISSN:  0167-6806     ISO Abbreviation:  Breast Cancer Res. Treat.     Publication Date:  2008 Nov 
Date Detail:
Created Date:  2008-09-30     Completed Date:  2008-12-10     Revised Date:  2013-06-06    
Medline Journal Info:
Nlm Unique ID:  8111104     Medline TA:  Breast Cancer Res Treat     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  141-7     Citation Subset:  IM    
Affiliation:
Department of Epidemiology, University of Michigan School of Public Health, 109 Observatory Street, Ann Arbor, MI 48109, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Aged
Breast Neoplasms / complications,  epidemiology*,  genetics*
Egypt / epidemiology
Epidemiologic Studies
Female
Humans
Immunoenzyme Techniques
Incidence
Inflammation
Medical Records
Middle Aged
Molecular Epidemiology
Prognosis
Tissue Array Analysis
United States / epidemiology
Vesicular Transport Proteins / genetics*
rho GTP-Binding Proteins / genetics*
Grant Support
ID/Acronym/Agency:
5 P30 CA46592/CA/NCI NIH HHS; CA77612/CA/NCI NIH HHS; K07 CA090241-01A2/CA/NCI NIH HHS; K07 CA90241/CA/NCI NIH HHS; P30 CA046592-21S1/CA/NCI NIH HHS; R03 CA117350/CA/NCI NIH HHS; R03 CA117350-01/CA/NCI NIH HHS; R25 CA112383/CA/NCI NIH HHS; R25 CA112383-01A2/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/LYVE1 protein, human; 0/RHOC protein, human; 0/Vesicular Transport Proteins; EC 3.6.5.2/rho GTP-Binding Proteins
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Microarray analysis of altered sphingolipid metabolism reveals prognostic significance of sphingosin...
Next Document:  The RAD51D E233G variant and breast cancer risk: population-based and clinic-based family studies of...